Paraneoplastic Disorders.

Area of Science:

• Neurology
• Immunology
• Oncology

Background:

• Paraneoplastic neurologic syndromes (PNS) involve autoimmune responses targeting the nervous system, often associated with specific cancers.
• These syndromes manifest with diverse clinical symptoms, including peripheral and central nervous system dysfunction.
• Advances in antibody testing have improved diagnostic capabilities for PNS.

Purpose of the Study:

• To review recent findings in paraneoplastic neurologic syndromes, focusing on pathogenic mechanisms, antibody targets, and clinical associations.
• To discuss the diagnostic challenges and implications of expanded paraneoplastic antibody testing.
• To highlight the varying prognoses and treatment strategies for different types of PNS.

Main Methods:

• Review of recent literature on paraneoplastic neurologic syndromes, encompassing peripheral and central nervous system disorders.
• Analysis of pathogenic mechanisms involving autoantibodies and T-cell responses.
• Evaluation of clinical manifestations, tumor associations, and diagnostic utility of antibody testing.

Main Results:

• Peripheral PNS like myasthenia gravis and Lambert-Eaton myasthenic syndrome are mediated by pathogenic autoantibodies.
• Syndromes associated with onconeuronal antibodies (e.g., anti-Hu) have strong cancer links and poor treatment response.
• Autoimmunity to CNS membrane proteins (e.g., NMDA receptor, LGI1) defines disorders with better prognoses and variable cancer associations.

Conclusions:

• Paraneoplastic neurologic syndromes present with varied clinical features, necessitating precise diagnosis through antibody testing.
• Treatment strategies involve addressing both the autoimmune response (immunotherapy) and the underlying malignancy.
• Further research, including animal models, is crucial for developing novel treatments for PNS.